EP3219328

JANSSEN BIOTECH, INC.
Application Number
EP17156111A
Filing Date
Dec 28, 2006
Status
Revoked
Mar 19, 2021
Grant Date
Jun 17, 2020
External Links
Slate, Register

Biblio Summary

The patent EP3219328B1 was granted on Jun 17, 2020 by Janssen Biotech, Inc. The patent is currently Revoked.

The table below shows 2 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

ABBVIE INC.Mar 17, 2021DEEMED NOT TO HAVE BEEN FILED
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGMar 17, 2021DEEMED NOT TO HAVE BEEN FILED

The table below shows the patents of Janssen Biotech, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3883606Safe And Effective Method Of Treating Ulcerative Colitis With Anti-Il12/Il23 AntibodyOct 4, 20235
EP2970980Manufacturing Methods To Control C-Terminal Lysine, Galactose And Sialic Acid Content In Recombinant ProteinsJul 27, 20221
EP3827845Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their UsesMar 30, 20225

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.